Phase I trial of in situ vaccination with autologous CCL21-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLC.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Aaron E. Lisberg, Bin Liu, Ramin Salehi-Rad, Jay M. Lee, Linh Tran, Kostyantyn Krysan, Raymond Lim, Camelia Dumitras, Zhe Jiang, Fereidoun Abtin, Robert Suh, Scott Genshaft, Scott Oh, Gregory A Fishbein, Ciara M O'Higgins, Shay Ashouri, Jonathan W. Goldman, David Elashoff, Edward B. Garon, Steven M. Dubinett, CCL21
Institution: University of California, Los Angeles
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4286297257